Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.51 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | REN | P00797 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 2/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.39 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14087065 | 1.00 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3CTSDREN | |
| SCHEMBL14741312 | 1.00 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3CTSDREN | |
| SCHEMBL7867639 | 1.00 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3CTSDREN | |
| SCHEMBL14741345 | 0.81 | CHRM2 (0.47) | SLC6A2SLC6A4SLC6A3CTSDALDH1A1 | |
| SCHEMBL4294468 | 0.80 | CTSD (0.60) | SLC6A2SLC6A4SLC6A3CTSDGBA1 | |
| SCHEMBL12627343 | 0.78 | SLC6A2 (0.41) | SLC6A2SLC6A4SLC6A3ALDH1A1TSHR | |
| SCHEMBL18484463 | 0.74 | KMT2A (0.41) | SLC6A2SLC6A4ALDH1A1TSHRMC4R | |
| SCHEMBL7867642 | 0.74 | KMT2A (0.41) | SLC6A2SLC6A4ALDH1A1TSHRMC4R | |
| SCHEMBL16422495 | 0.74 | CTSD (0.54) | SLC6A2SLC6A4SLC6A3CTSDREN | |
| SCHEMBL14820140 | 0.74 | KMT2A (0.41) | SLC6A2SLC6A4ALDH1A1TSHRMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2750678-B1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS INC (US) | 2017-03-22 | — | — | EP | disclosed |
| WO-2016025932-A1 | SUBSTITUTED POLYCYCLIC ANTIBACTERIAL COMPOUNDS | PTC THERAPEUTICS, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| US-20150038438-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. | 2015-02-05 | — | — | US | disclosed |
| EP-2750678-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC Therapeutics, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013033228-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-7951805-B2 | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase | XENON PHARMACEUTICALS INC. (CA) | 2011-05-31 | — | — | US | disclosed |
| US-7951805-B2 | Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase | XENON PHARMACEUTICALS INC. (CA) | 2011-05-31 | — | — | US | disclosed |
| US-20080194547-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| US-20070299081-A1 | Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa Desaturase | XENON PHARMACEUTICALS INC. (CA) | 2007-12-27 | — | — | US | disclosed |
| US-20070299081-A1 | Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa Desaturase | XENON PHARMACEUTICALS INC. (CA) | 2007-12-27 | — | — | US | disclosed |
| EP-1799668-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDIATORS OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006034338-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDIATORS OF STEAROYL-COA DESATURASE | XENON PHARMACEUTICALS INC. (CA) | 2006-03-30 | — | — | WO | disclosed |
| US-6310216-B1 | Special 3-azabicyclo[3.1.0]hexanes, method for producing and modifying the same, and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2001-10-30 | — | — | US | disclosed |
| EP-1000026-A1 | SPECIAL 3-AZABICYCLO 3.1.0]HEXANES, METHOD FOR PRODUCING AND MODIFYING THE SAME, AND THEIR USE | Bayer Aktiengesellschaft (DE) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999006368-A1 | SPECIAL 3-AZABICYCLO[3.1.0]HEXANES, METHOD FOR PRODUCING AND MODIFYING THE SAME, AND THEIR USE | BAYER AKTIENGESELLSCHAFT (DE) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038438-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | MRPL21, SLC11A2, CLPP | SLC6A2 3627/4885SLC6A4 4244/4885SLC6A3 3405/4885 |
| US-20070299081-A1 | Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa Desaturase | SCD, SCD5, NR1H2 | SLC6A2 4724/4885SLC6A4 4725/4885SLC6A3 4773/4885 |
| US-20080194547-A1 | Antibacterial Agents | NQO2, NQO1, NDUFV2 | SLC6A2 1207/4885SLC6A4 1924/4885SLC6A3 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.